VLON Insider Trading

Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 37.30%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Vallon Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Vallon Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Vallon Pharmaceuticals Share Price & Price History

Current Price: $0.76
Price Change: Price Decrease of -0.02 (-2.56%)
As of 03/28/2024 01:00 AM ET

This chart shows the closing price history over time for VLON up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Vallon Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/4/2021Leanne M. KellyCFOBuy50$122.40$6,120.00121View SEC Filing Icon  
6/2/2021Leanne M. KellyCFOBuy121$120.00$14,520.00121View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Vallon Pharmaceuticals (NASDAQ:VLON)

8.74% of Vallon Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at VLON by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Vallon Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/15/2023Virtu Financial LLC106,120$30K0.0%-18.5%0.833%Search for SEC Filing on Google Icon
11/7/2022Virtu Financial LLC130,239$37K0.0%N/A1.912%Search for SEC Filing on Google Icon
8/13/2022Renaissance Technologies LLC78,888$50K0.0%N/A1.158%Search for SEC Filing on Google Icon
5/13/2022Vanguard Group Inc.101,664$0.19M0.0%-38.4%1.493%Search for SEC Filing on Google Icon
2/15/2022Laidlaw Wealth Management LLC20,200$0.12M0.0%N/A0.296%Search for SEC Filing on Google Icon
12/27/2021Zeke Capital Advisors LLC20,000$0.15M0.0%-33.3%0.294%Search for SEC Filing on Google Icon
11/5/2021Advisor Group Holdings Inc.6,890$50K0.0%+57.4%0.101%Search for SEC Filing on Google Icon
8/17/2021Zeke Capital Advisors LLC30,000$0.16M0.0%N/A0.440%Search for SEC Filing on Google Icon
8/13/2021Altium Capital Management LP161,440$0.88M0.2%-46.2%2.370%Search for SEC Filing on Google Icon
8/13/2021Murchinson Ltd.194,900$1.06M0.4%N/A2.861%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC13,116$71K0.0%N/A0.193%Search for SEC Filing on Google Icon
8/4/2021Envestnet Asset Management Inc.17,513$95K0.0%+48.7%0.257%Search for SEC Filing on Google Icon
5/18/2021Millennium Management LLC28,461$0.13M0.0%N/A0.418%Search for SEC Filing on Google Icon
5/17/2021Ikarian Capital LLC140,000$0.65M0.0%N/A2.055%Search for SEC Filing on Google Icon
5/6/2021Altium Capital Management LP300,000$1.39M0.4%N/A4.405%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Vallon Pharmaceuticals logo
Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.
Read More on Vallon Pharmaceuticals

Today's Range

Now: $0.76
Low: $0.76
High: $0.80

50 Day Range

MA: $0.67
Low: $0.27
High: $2.87

52 Week Range

Now: $0.76
Low: $0.21
High: $12.92

Volume

120,406 shs

Average Volume

5,783,646 shs

Market Capitalization

$10.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A